The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Risk of Endometrial Cancer Following Estrogen Replacement With and Without Progestins
Abstract
BACKGROUND: Unopposed estrogen replacement therapy (i.e., estrogen without progestins) increases the risk of endometrial cancer. In this study, we examined the endometrial cancer risk associated with combined estrogen-progestin regimens currently in use, since the safety profiles of these regimens have not been clearly defined. METHODS: We conducted a nationwide population-based, case-control study in Sweden of postmenopausal women aged 50-74 years. We collected information on use of hormone replacement from 709 case patients with incident endometrial cancer and from 3368 control subjects. We used unconditional logistic regression to calculate odds ratios (ORs) as estimates of relative risks. All individual comparisons were made with women who never used the respective hormone replacement regimens. RESULTS: Treatment with estrogens alone was associated with a marked duration- and dose-dependent increase in the relative risk of endometrial cancer. Five or more years of treatment had an OR of 6.2 for estradiol (95% confidence interval [CI] = 3.1-12.6) and of 6.6 for conjugated estrogens (95% CI = 3.6-12.0). Following combined estrogen-progestin use, the association was considerably weaker than that for estrogen alone; the OR was 1.6 (95% CI = 1.1-2.4) after 5 or more years of use. This increase in risk was confined to women with cyclic use of progestins, i.e., fewer than 16 days per cycle (most commonly 10 days per cycle [OR = 2.9; 95% CI = 1.8-4.6 for 5 or more years of use]), whereas continuous progestin use along with estrogens was associated with a reduced risk (OR = 0.2; 95% CI = 0.1-0.8 for 5 or more years of use). CONCLUSION: The risk of developing endometrial cancer is increased after long-term use of estrogens without progestins and with cyclically added progestins. Continuously added progestins may be needed to minimize the endometrial cancer risk associated with estrogen replacement therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Statistical methods in cancer research. Volume I - The analysis of case-control studies.
Breslow, N. E., & Day, N. E. (1980) · PubMed · Cited by 4,988
Cancer Epidemiology and Prevention
(2006) · doi:10.1093/acprof:oso/9780195149616.001.0001 · Cited by 3,369
Physiological Action of Progesterone in Target Tissues*
Graham, J. D., & Clarke, C. L. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.4.0308 · Cited by 1,008
Hormone replacement therapy and endometrial cancer risk: A meta-analysis
GRADY, D., GEBRETSADIK, T., KERLIKOWSKE, K., ERNSTER, V, & PETITTI, D. (1995) · Obstetrics & Gynecology · doi:10.1016/0029-7844(94)00383-o · Cited by 962
Beresford, S. A., Weiss, N. S., Voigt, L. F., & McKnight, B. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07365-5 · Cited by 446
Persson, I., Adami, H. O., Bergkvist, L., Lindgren, A., Pettersson, B., Hoover, R., & Schairer, C. (1989) · BMJ · doi:10.1136/bmj.298.6667.147 · Cited by 403
Self-citationMechanisms of Carcinogenesis in Risk Identification
Vainio, H. (1992) · Medical Entomology and Zoology · Cited by 348
Estrogen-Progestin Replacement Therapy and Endometrial Cancer
Pike, M. C., Peters, R. K., Cozen, W., Probst-Hensch, N. M., Wan, P. C., Mack, T. M., & Felix, J. C. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.15.1110 · Cited by 315
Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer
Voigt, L. F., Weiss, N. S., Chu, J., Daling, J. R., McKnight, B., & van Belle, G. (1991) · The Lancet · doi:10.1016/0140-6736(91)90417-n · Cited by 276
Cited by
Breast cancer and hormone-replacement therapy in the Million Women Study
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14065-2 · Cited by 2,993
2016 IMS Recommendations on women’s midlife health and menopause hormone therapy
Baber, R. J., Panay, N., & Fenton, A. (2016) · Climacteric · doi:10.3109/13697137.2015.1129166 · Cited by 964
Ovarian cancer and hormone replacement therapy in the Million Women Study
Beral, V. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60534-0 · Cited by 937
Smith, R. A., von Eschenbach, A. C., Wender, R., Levin, B., Byers, T., Rothenberger, D., Brooks, D., Creasman, W., Cohen, C., Runowicz, C., et al. (2001) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.51.1.38 · Cited by 821
Barth, C., Villringer, A., & Sacher, J. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00037 · Cited by 711
Metadata
- Authors
- Weiderpass, E., Adami, H.-O., Baron, J. A., Magnusson, C., Bergstrom, R., Lindgren, A., Correia, N., & Persson, I.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-07-07
- Volume
- 91
- Issue
- 13
- Pages
- 1131-1137
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2126845172
- Cited by
- 471
- References
- 20
- FWCI
- 23.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk of Endometrial Cancer Following Estrogen Replacement With and Without Progestins. https://app.cochat.ai/papers/10.1093/jnci/91.13.1131
- The paper
- Weiderpass, E., Adami, H.-O., Baron, J. A., Magnusson, C., Bergstrom, R., Lindgren, A., Correia, N., & Persson, I. (1999). Risk of Endometrial Cancer Following Estrogen Replacement With and Without Progestins. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/91.13.1131
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.